Salute e Benessere
Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight
Discover which therapies are expected to grab the major cancer cachexia treatment market share @
Cancer cachexia is a multifactorial wasting disorder commonly observed in advanced stages of cancer. It is characterized by a progressive depletion of skeletal muscle and fat, resulting in profound weakness. Unlike general malnutrition, cancer cachexia does not improve with nutritional support alone. The condition is largely driven by systemic inflammation, with cytokines, proteins released by both tumor and host cells, playing a central role. These inflammatory mediators disrupt normal metabolic processes, triggering appetite loss (anorexia), insulin resistance (reduced glucose utilization), and a metabolic shift favoring tissue breakdown (catabolism) over tissue synthesis. This leads to a persistent energy deficit, especially in aggressive cancers such as pancreatic, lung, and head and neck cancers.
Diagnosing cancer cachexia is challenging due to the absence of a single diagnostic marker, requiring a comprehensive evaluation. This includes nutritional assessment tools like the Patient-Generated Subjective Global Assessment (PG-SGA) or Mini Nutritional Assessment (MNA), body composition analysis through imaging methods like computed tomography (CT), the gold standard, or alternatives such as dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), as well as muscle strength tests like handgrip dynamometry.
Laboratory indicators such as low serum albumin and elevated C-reactive protein (CRP) can aid diagnosis but lack specificity. Composite scoring systems like the modified Glasgow Prognostic Score (mGPS) and the Cancer Cachexia Score (CASCO) offer a more holistic approach by integrating clinical, metabolic, and functional parameters to stage the condition and predict clinical outcomes.
The cancer cachexia epidemiology section provides insights into the historical and current cancer cachexia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The cancer cachexia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Progestational agents like are known to stimulate appetite and promote weight gain in individuals suffering from anorexia and cachexia. A randomized, prospective clinical study comparing megestrol (800 mg/day) with dexamethasone (0.75 mg four times daily) found that both drugs had similar effects on enhancing appetite. However, megestrol was more frequently associated with thromboembolic complications, whereas dexamethasone was linked to side effects such as muscle weakness, Cushingoid appearance, and peptic ulcers.
Although have shown effectiveness in treating cancer-related anorexia and cachexia, they generally do not produce significant long-term benefits for most patients. As a result, alternative interventions, including enteral and parenteral nutrition, have been widely explored. In January 2021 , was approved in Japan for the treatment of cancer cachexia in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Cytokine-targeted therapies have also been investigated. These therapies affect a range of tissues, including bone marrow, muscle, liver, fat, endothelial cells, and neurons, triggering complex biological responses that contribute to the muscle and weight loss seen in cachexia. Key cytokines implicated include tumor necrosis factor (TNF)-α, interleukins IL-1 and IL-6, and interferon-γ (IFN-γ). These molecules share similar metabolic roles and often act in a coordinated or synergistic manner. Therefore, treatment strategies have focused on inhibiting either their production or their downstream effects.
To know more about cancer cachexia treatment guidelines, visit @
Discover more about cancer cachexia drugs in development @
The cancer cachexia market dynamics are expected to change in the coming years. Cancer cachexia affects a significant portion of , creating a strong demand for effective therapies and presenting a valuable opportunity for companies to develop treatments, given the current .
Furthermore, potential therapies are being investigated for the treatment of cancer cachexia, and it is safe to predict that the treatment space will significantly impact the cancer cachexia market during the forecast period. Moreover, the
with improved efficacy and a further
are expected to drive the growth of the cancer cachexia market in the 7MM.
However, several factors may impede the growth of the cancer cachexia market. Studies have shown that cancer patients with cachexia respond poorly to chemotherapy, face a , with mortality rates ranging from 0–80%, and at least die from cachexia rather than the cancer itself.
Moreover, cancer cachexia treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the cancer cachexia market growth may be offset by , , , and a . In addition, the about the disease may also impact the cancer cachexia market growth.
Download the report to understand which factors are driving cancer cachexia market trends @
report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha inhibitors companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cancer cachexia companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cancer anorexia companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cachexia companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cancer-cachexia-market-anticipates-impressive-growth-trajectory-at-a-cagr-of-8-9-during-the-forecast-period-20252034--delveinsight-302500954.html